Hao-Ming Lin

Hao-Ming Lin

Auto-generated profile, based on publicly available information

Hao-Ming Lin

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Biliary-Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
HLHaoming Lin
Haoming Lin
RZRui Zhang
Rui Zhang
WWWenrui Wu
Wenrui Wu
LLLiming Lei
Liming Lei
Hepatocellular carcinoma (HCC) has high morbidity and mortality. MicroRNAs (miRNAs), which could be regulated by cancer‐derived exosomes, play critical regulatory roles in the initiation and development of cancer. However, the expressions, effects, and mechanisms of abundant miRNAs regulated by HCC cancer‐derived exosomes in HCC remain largely unclear. Exosomes of HepG2 cells under heat shock, TGF‐β1, doxorubicin, acid and hypoxia/reoxygenation (H/R) conditions, and exosomes were successfully identified by transmission electron microscopy and Western blot analysis. The identified exosomes were then applied to evaluate the miRNA expression profiles by RNA sequencing. Mechanically, we discovered that doxorubicin was upregulated, TGF‐β1 downregulated the expressions of Vps4A, Rab27A, Alix, and Hrs in HepG2 cells and exosomes, and Vps4A and Rab27A, as target genes for miR‐4454, could also be downregulated by miR‐4454. Functionally, we revealed that miR‐4454 inhibitor and miR‐4454 inhibitor‐mediated exosomes could markedly suppress proliferation, migration, invasion, and vascularization and accelerate cycle arrest, apoptosis, and ROS of HepG2 cells. This study provided many potential HCC cancer‐derived exosome‐mediated miRNAs in HCC under 5 different stimulus conditions. Meanwhile, we certified that miR‐4454 in exosomes could provide a novel and effective mechanism for HCC function.

22 October 2022 in Asian Journal of Surgery
Verified
Journal Article
Open access
TZTaifeng Zhu
Taifeng Zhu
KZKe Zhu
Ke Zhu
JSJian Sun
Jian Sun
CLChao Liu
Chao Liu
HLHaoming Lin
Haoming Lin
RZRui Zhang
Rui Zhang
Although laparoscopic common bile duct exploration (LCBDE) is considered a safe and effective method for the removal of bile duct stones, selecting primary duct closure (PDC) or T-tube drainage (TTD) following choledochotomy remains controversial. This study aims to explore the clinical effects of PDC and TTD after LCBDE. We retrospectively analyzed clinical data of 348 patients with choledocholithiasis treated with LCBDE from January 2016 to October 2020. All patients were divided into PDC (225 cases) and TTD (123 cases) groups. Propensity score matching (PSM) was performed. We compared operative parameters and outcomes. After matching (n = 116/group), no significant difference was observed between the two groups (P > 0.05) regarding intra-abdominal infection, incision infection, bile leakage, and retained stones. In terms of operation time, intraoperative blood loss, postoperative hospital stay, postoperative exhaust time, postoperative antibiotic use time, and postoperative abdominal drainage time, PDC group was obviously superior to TTD group (P < 0.05). Primary closure following LCBDE is considered a safe and effective alternative to T-tube drainage.

1 December 2021 in Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
PDF file
WCWei Chen
Wei Chen
MHMing-Juan Hu
Ming-Juan Hu
XZXiao-Lan Zhong
Xiao-Lan Zhong
LJLin-Hua Ji
Lin-Hua Ji
JWJian Wang
Jian Wang
HLHao-Ming Lin
Hao-Ming Lin
Screening of a novel autophagy-related prognostic signature and therapeutic targets in hepatocellular carcinoma Wei Chen, Ming-Juan Hu, Xiao-Lan Zhong, Lin-Hua Ji, Jian Wang, Cheng-Fang Zhang, Rui Zhang, Hao-Ming Lin


17 July 2019 in Science China Life Sciences
Verified
Journal Article
Closed access
PDF file
RZRui Zhang
Rui Zhang
HLHao-Ming Lin
Hao-Ming Lin
ZCZhao-Xi Cai
Zhao-Xi Cai
SDSu-Juan Du
Su-Juan Du
HZHong Zeng
Hong Zeng
CLChao Liu
Chao Liu

28 February 2025 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
QLQin-Qin Liu
Qin-Qin Liu
JYJian Yan
Jian Yan
YYYan-Fang Ye
Yan-Fang Ye
CYCai-Ni Yang
Cai-Ni Yang
ZCZhi-Jun Chen
Zhi-Jun Chen
RZRui Zhang
Rui Zhang
Gallbladder carcinoma (GBC) is an extremely aggressive tumor of the biliary tract with a bleak prognosis, and the evidence supporting the benefit of available systemic therapy for advanced GBC is scarce. Herein, this study intended to investigate the real-world outcome of chemotherapy combined with programmed death-1 (PD-1) inhibitor for the management of unresectable or recurrent GBC. From January 2018 to December 2023, consecutive patients who were treated with systematic treatment, including chemotherapy or the combination of chemotherapy plus PD-1 inhibitor, for unresectable or recurrent GBC were retrospectively identified. Clinical data regarding baseline characteristics, therapeutic response, adverse events (AEs), and oncological outcomes were collected. The eligible patients were allocated to combination therapy arm (n = 46) and mono-chemotherapy arm (n = 19). After propensity score matching (PSM), 16 patients were allocated in each arm. The overall survival (OS) and progression-free survival (PFS) of combination therapy were marginally superior to mono-chemotherapy both before and after PSM. The combination therapy exhibited advantage over mono-chemotherapy in regards to partial response (PR) (before PSM: P = 0.009; after PSM: P = 0.037) and objective response rate (ORR) (before PSM: P = 0.006; after PSM: P = 0.015). In combined therapy cohort, 1 patient achieve a complete response, and 13 patients were assessed as appropriate for surgical excision, among which 1 patient refused further surgical intervention. In patients with unresectable or recurrent GBC, the combination of chemotherapy and PD-1 inhibitor as first-line therapy exhibited prolonged OS and PFS, and increased PR and ORR over those receiving chemotherapy alone, with an acceptable toxicity profile. The combination therapy may be a potential conversion therapy in unresectable GBC patients.